Breaking News Instant updates and real-time market news.

ONCE

Spark Therapeutics

$85.15

-1.95 (-2.24%)

, AVXS

AveXis

$92.11

-4.03 (-4.19%)

09:51
09/23/17
09/23
09:51
09/23/17
09:51

Gene therapy may be nearing 'major breakthrough,' Baron's says

Gene therapy is rapidly emerging as one of the most exciting areas in biotechnology, and generating new hope for patients with rare and often deadly inherited diseases, Andre Bary writes in this week's edition of Barron's. The first regulatory approval for replacement gene therapy could come as soon as January, if the FDA gives the go-ahead to Spark Therapeutics (ONCE) for its one-time treatment that targets a rare, inherited retinal condition leading to blindness, he adds. Other publicly traded companies developing treatments in this area include AveXis' (AVXS), Regenxbio (RGNX), Audentes Therapeutics (BOLD), and Voyager Therapeutics (VYGR).Reference Link

ONCE

Spark Therapeutics

$85.15

-1.95 (-2.24%)

AVXS

AveXis

$92.11

-4.03 (-4.19%)

RGNX

Regenxbio

$28.25

-1.15 (-3.91%)

BOLD

Audentes Therapeutics

$27.31

-0.1 (-0.36%)

VYGR

Voyager Therapeutics

$17.50

-0.22 (-1.24%)

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

  • 12

    Oct

  • 12

    Jan

  • 22

    Sep

ONCE Spark Therapeutics
$85.15

-1.95 (-2.24%)

09/14/17
RBCM
09/14/17
INITIATION
Target $100
RBCM
Outperform
Spark Therapeutics initiated with an Outperform at RBC Capital
RBC Capital analyst Matthew Eckler started Spark Therapeutics with an Outperform rating and $100 price target. The analyst sees the expected upcoming approval of Luxturna as having "broad positive read-through" to the company's platform. He's a buyer ahead of next month's FDA panel.
09/06/17
LEHM
09/06/17
INITIATION
Target $104
LEHM
Overweight
Spark named top pick in U.S. SMid-Cap Biotechnology at Barclays
Barclays analyst Gena Wang after the close initiated coverage of the U.S. Small & Mid Cap Biotechnology industry with a Positive view. Her top industry pick is Spark Therapeutics (ONCE). The analyst sees de-risking clinical data for several novel therapies in the biotech sector, namely from Spark, BioMarin (BMRN), AveXis (AVXS), Alnylam (ALNY) and Puma Biotechnology (PBYI). Wang believes Spark's Luxturna in RPE-65-mediated inherited retinal dystrophies could be disruptive to current treatment paradigms.
09/06/17
LEHM
09/06/17
INITIATION
Target $104
LEHM
Overweight
Spark Therapeutics initiated with an Overweight at Barclays
Barclays analyst Gena Wang started Spark Therapeutics with an Overweight rating and $104 price target. The analyst views the company's Luxturna as a potential disruptive treatment in inherited retinal dystrophies.
09/21/17
JEFF
09/21/17
NO CHANGE
Target $95
JEFF
Buy
Jefferies sees Spark rallying 5%-7% on positive FDA panel
Jefferies analyst Michael Yee sees a "high likelihood" for a positive FDA panel on October 12 for Spark Therapeutics' SPK-RPE65, setting up approval for the first gene therapy drug for rare blindness on or before the FDA action date of January 12, 2018. The analyst sees 5%-7% share upside on a positive vote, mostly as a "de-risking event and also a positive read-through derivative to gene therapy companies as FDA starts to approve gene therapy drugs." He keeps a Buy rating on Spark with a $95 price target.
AVXS AveXis
$92.11

-4.03 (-4.19%)

09/06/17
LEHM
09/06/17
INITIATION
LEHM
Overweight
AveXis initiated with an Overweight at Barclays
Barclays initiated AveXis with an Overweight rating and $124 price target, citing AVXS-101 showing "impressive" clinical benefit in Ph1/2 study, which could result in it becoming a strong competitor to Spinraza.
09/14/17
RBCM
09/14/17
INITIATION
Target $92
RBCM
Sector Perform
AveXis initiated with a Sector Perform at RBC Capital
RBC Capital analyst Brian Abrahams started AveXis with a Sector Perform rating and $92 price target.
08/29/17
08/29/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Esperion (ESPR) initiated with an Outperform at Northland. 2. Carter's (CRI) initiated with an Outperform at Macquarie. 3. DarioHealth (DRIO) initiated with a Buy at Aegis. 4. Helen of Troy (HELE) initiated with an Underperform at BofA/Merrill. 5. AveXis (AVXS) initiated with a Reduce at Nomura Instinet. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
RGNX Regenxbio
$28.25

-1.15 (-3.91%)

09/05/17
CHDN
09/05/17
NO CHANGE
Target $75
CHDN
Buy
Regenxbio price target raised to $75 from $55 at Chardan
08/16/17
EVER
08/16/17
INITIATION
Target $25
EVER
Outperform
Regenxbio initiated with an Outperform at Evercore ISI
Evercore ISI analyst Josh Schimmer initiated Regenxbio with an Outperform and a $25 price target.
09/19/17
SBSH
09/19/17
DOWNGRADE
Target $5.5
SBSH
Sell
Dimension Therapeutics downgraded to Sell from Neutral at Citi
Citi analyst Joel Beatty downgraded Dimension Therapeutics (DMTX) to Sell saying his base case is now the takeover proposed by Ultragenyx (RARE) will go ahead. Since Dimension s currently trading at a small premium to the $5.50 per share proposal, the analyst downgraded the stock to Sell. Beatty sees a "small but real potential" for a higher bid to come in. He believes, however, that a successful bid from Regenxbio (RGNX) would likely need to be double its original offer. The analyst raised his price target for Dimension shares to $5.50 from $3.41.
09/19/17
BARD
09/19/17
NO CHANGE
BARD
Outperform
Ultragenyx deal for Dimension would be good strategic fit, says Baird
Baird analyst Michael Ulz noted Ultragenyx (RARE) topped Regenxbio's (RGNX) bid for Dimension Therapeutics (DMTX) with a $5.50 per share offer of its own. He views the proposed acquisition of Dimension as a good strategic fit that would add a gene therapy platform and expand the early-stage pipeline. Ulz keeps an Outperform rating on Ultragenyx shares.
BOLD Audentes Therapeutics
$27.31

-0.1 (-0.36%)

08/16/17
EVER
08/16/17
INITIATION
Target $23
EVER
Outperform
Audentes Therapeutics initiated with an Outperform at Evercore ISI
Evercore ISI analyst Josh Schimmer initiated Audentes Therapeutics with an Outperform and a $23 price target.
05/01/17
LEER
05/01/17
INITIATION
Target $22
LEER
Outperform
Audentes Therapeutics initiated with an Outperform at Leerink
Leerink analyst Joseph Schwartz started Audentes Therapeutics with an Outperform rating and $22 price target as he believes catalysts over the next 12 months have the potential to generate enthusiasm for the company's approach, which appears de-risked by strong preclinical animal model data.
10/10/16
PIPR
10/10/16
NO CHANGE
Target $24
PIPR
Overweight
AveXis data bodes well for Audentes gene therapy program, says Piper Jaffray
Piper Jaffray analyst Joshua Schimmer said additional data presented by AveXis (AVXS) from its ongoing Phase 1/2 trial in infantile-onset spinal muscular atrophy "augurs well" for Audentes Therapeutics' (BOLD) gene therapy program for X-linked myotubular myopathy, as he sees several points of similarity that provide a positive read-through though the companies are targeting different diseases. Schimmer, who does not have a rating on AveXis, reiterates his Overweight rating and $24 price target on Audentes shares.
VYGR Voyager Therapeutics
$17.50

-0.22 (-1.24%)

03/01/17
NOMU
03/01/17
INITIATION
Target $31
NOMU
Buy
Voyager Therapeutics initiated with a Buy at Nomura
Nomura initiated Voyager Therapeutics with a Buy and a $31 price target.
03/31/17
STFL
03/31/17
NO CHANGE
STFL
Voyager Therapeutics has reached attractive entry point, says Stifel
After meeting with Voyager's CEO, Stifel analyst Katherine Breedis says that the company "continues to make solid progress" with its top drug, VY-AADC01. The analyst notes that the company is slated to report Phase 1B six month data for the drug in the middle of this year, and she says that it could be an important positive turning point for the shares. The analyst adds that the data may have been "de-risked" by recent improved outcomes reported by the company. Breedis thinks that VY-AADC01 has several key potential positive catalysts over the next 6-9 months,. She thinks that the stock has reached an attractive entry point and keeps a $33 price target and a Buy rating on the stock.
08/16/17
EVER
08/16/17
INITIATION
Target $21
EVER
Outperform
Voyager Therapeutics initiated with an Outperform at Evercore ISI
Evercore ISI analyst Josh Schimmer initiated Voyager Therapeutics with an Outperform and a $21 price target.
07/28/17
STFL
07/28/17
INITIATION
STFL
Buy
Voyager Therapeutics coverage resumed with a Buy at Stifel
Stifel analyst Thmas Shrader resumed coverage of Voyager with a $20 price target and a Buy rating. He thinks that the company's lead drug, a treatment for Parkinson's "has great promise."

TODAY'S FREE FLY STORIES

SPX

S&P 500

, SPY

SPDR S&P 500 ETF Trust

$273.45

2.0503 (0.76%)

14:08
02/21/18
02/21
14:08
02/21/18
14:08
Hot Stocks
Fed sees core inflation reaching 2% in 2019, minutes show »

Minutes from the last…

SPX

S&P 500

SPY

SPDR S&P 500 ETF Trust

$273.45

2.0503 (0.76%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MCS

Marcus

$25.85

0.75 (2.99%)

14:06
02/21/18
02/21
14:06
02/21/18
14:06
Hot Stocks
Marcus raises quarterly cash dividend to 15c per share »

Marcus approved a 20%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 23

    May

SPX

S&P 500

, SPY

SPDR S&P 500 ETF Trust

$273.33

1.93 (0.71%)

14:06
02/21/18
02/21
14:06
02/21/18
14:06
General news
Fed sees tax cuts boosting GDP growth 'moderately' over medium term »

Minutes from the last…

SPX

S&P 500

SPY

SPDR S&P 500 ETF Trust

$273.33

1.93 (0.71%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CGG

CGG SA

$3.95

-0.26 (-6.18%)

14:03
02/21/18
02/21
14:03
02/21/18
14:03
Hot Stocks
Breaking Hot Stocks news story on CGG SA »

CGG SA trading halted,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OSIS

OSI Systems

$63.11

0.03 (0.05%)

14:00
02/21/18
02/21
14:00
02/21/18
14:00
Initiation
OSI Systems initiated  »

OSI Systems initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Mar

  • 23

    May

  • 14

    Jun

TSN

Tyson Foods

$76.64

0.51 (0.67%)

14:00
02/21/18
02/21
14:00
02/21/18
14:00
Options
Notable call buying in Tyson Foods »

Notable call buying in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FEYE

FireEye

$16.39

0.05 (0.31%)

, CHKP

Check Point

$102.21

-1.07 (-1.04%)

13:59
02/21/18
02/21
13:59
02/21/18
13:59
Hot Stocks
SEC adopts statement and guidance on public company cybersecurity disclosures »

The Securities and…

FEYE

FireEye

$16.39

0.05 (0.31%)

CHKP

Check Point

$102.21

-1.07 (-1.04%)

SYMC

Symantec

$27.02

-0.53 (-1.92%)

IMPV

Imperva

$46.85

0.75 (1.63%)

CUDA

Barracuda

PANW

Palo Alto Networks

$166.78

3.86 (2.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 26

    Feb

  • 26

    Feb

  • 27

    Feb

  • 01

    Mar

  • 04

    Mar

  • 13

    Mar

  • 14

    Mar

  • 29

    Mar

CBRL

Cracker Barrel

$161.88

-11.86 (-6.83%)

13:59
02/21/18
02/21
13:59
02/21/18
13:59
Recommendations
Cracker Barrel analyst commentary  »

Cracker Barrel conference…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jun

QCOM

Qualcomm

$63.99

-0.86 (-1.33%)

, AVGO

Broadcom

$249.62

0.73 (0.29%)

13:53
02/21/18
02/21
13:53
02/21/18
13:53
Hot Stocks
Qualcomm says reduced Broadcom proposal makes 'inadequate offer even worse' »

Qualcomm (QCOM) issued a…

QCOM

Qualcomm

$63.99

-0.86 (-1.33%)

AVGO

Broadcom

$249.62

0.73 (0.29%)

NXPI

NXP Semiconductors

$125.56

7.06 (5.96%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 06

    Mar

  • 22

    Mar

  • 23

    Mar

  • 27

    Mar

  • 28

    Mar

NEM

Newmont Mining

$38.54

0.15 (0.39%)

, HRL

Hormel Foods

$33.01

-0.795 (-2.35%)

13:51
02/21/18
02/21
13:51
02/21/18
13:51
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

NEM

Newmont Mining

$38.54

0.15 (0.39%)

HRL

Hormel Foods

$33.01

-0.795 (-2.35%)

APA

Apache

$37.26

-1.04 (-2.72%)

LDOS

Leidos

$65.94

-0.29 (-0.44%)

W

Wayfair

$96.98

0.68 (0.71%)

OA

Orbital ATK

$131.95

0.13 (0.10%)

TREE

LendingTree

$379.05

0.1 (0.03%)

SFM

Sprouts Farmers Market

$26.00

-1.02 (-3.78%)

TPX

Tempur Sealy

$55.77

1.97 (3.66%)

SAFM

Sanderson Farms

$131.44

-1.97 (-1.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 21

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 25

    Feb

  • 28

    Feb

  • 07

    Mar

  • 08

    Mar

  • 20

    Mar

  • 29

    Mar

QCOM

Qualcomm

$63.99

-0.86 (-1.33%)

, AVGO

Broadcom

$249.62

0.73 (0.29%)

13:51
02/21/18
02/21
13:51
02/21/18
13:51
Hot Stocks
Breaking Hot Stocks news story on Qualcomm, Broadcom »

Qualcomm says Broadcom…

QCOM

Qualcomm

$63.99

-0.86 (-1.33%)

AVGO

Broadcom

$249.62

0.73 (0.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 06

    Mar

QCOM

Qualcomm

$63.99

-0.86 (-1.33%)

, AVGO

Broadcom

$249.62

0.73 (0.29%)

13:50
02/21/18
02/21
13:50
02/21/18
13:50
Hot Stocks
Breaking Hot Stocks news story on Qualcomm, Broadcom »

Qualcomm says…

QCOM

Qualcomm

$63.99

-0.86 (-1.33%)

AVGO

Broadcom

$249.62

0.73 (0.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 06

    Mar

ETP

Energy Transfer Partners

$18.23

-0.05 (-0.27%)

, CLR

Continental Resources

$53.60

-1.13 (-2.06%)

13:50
02/21/18
02/21
13:50
02/21/18
13:50
Earnings
Notable companies reporting after market close »

Notable companies…

ETP

Energy Transfer Partners

$18.23

-0.05 (-0.27%)

CLR

Continental Resources

$53.60

-1.13 (-2.06%)

ETE

Energy Transfer Equity

$16.25

-0.259 (-1.57%)

SNPS

Synopsys

$89.76

0.69 (0.77%)

WPX

WPX Energy

$13.73

-0.21 (-1.51%)

ROKU

Roku

$51.18

3.05 (6.34%)

WEN

Wendy's

$16.10

-0.29 (-1.77%)

CAR

Avis Budget

$39.94

-0.08 (-0.20%)

WLL

Whiting Petroleum

$23.09

-0.41 (-1.74%)

CAKE

Cheesecake Factory

$45.61

-0.92 (-1.98%)

JACK

Jack in the Box

$88.18

-3.42 (-3.73%)

SAM

Boston Beer

$196.80

3.55 (1.84%)

P

Pandora

$5.00

-0.335 (-6.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 23

    Feb

  • 26

    Feb

  • 26

    Feb

  • 27

    Feb

  • 05

    Mar

  • 07

    Mar

  • 21

    Mar

  • 30

    May

RCII

Rent-A-Center

$8.93

-0.62 (-6.49%)

13:50
02/21/18
02/21
13:50
02/21/18
13:50
Recommendations
Rent-A-Center analyst commentary  »

Rent-A-Center price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

13:50
02/21/18
02/21
13:50
02/21/18
13:50
General news
FOMC minutes preview: the minutes are likely to have something for everyone »

FOMC minutes preview: the…

AAPL

Apple

$171.85

-0.58 (-0.34%)

13:49
02/21/18
02/21
13:49
02/21/18
13:49
Periodicals
Apple receives EEC approval for two mysterious iPads, Verge reports »

The Eurasian Economic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

SPB

Spectrum Brands

$101.13

-0.77 (-0.76%)

13:45
02/21/18
02/21
13:45
02/21/18
13:45
Options
Spectrum Brands call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 07

    Mar

13:45
02/21/18
02/21
13:45
02/21/18
13:45
General news
Breaking General news story  »

FOMC Minutes to be…

IART

Integra LifeSciences

$51.63

-0.63 (-1.21%)

13:43
02/21/18
02/21
13:43
02/21/18
13:43
Hot Stocks
Breaking Hot Stocks news story on Integra LifeSciences »

Champlain Investment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 27

    Mar

NCI

Navigant Consulting

$21.66

2.92 (15.58%)

13:43
02/21/18
02/21
13:43
02/21/18
13:43
Downgrade
Navigant Consulting rating change  »

Navigant Consulting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NCI

Navigant Consulting

$21.68

2.94 (15.69%)

13:40
02/21/18
02/21
13:40
02/21/18
13:40
Downgrade
Navigant Consulting rating change  »

Navigant Consulting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TWTR

Twitter

$33.74

0.9 (2.74%)

13:38
02/21/18
02/21
13:38
02/21/18
13:38
Hot Stocks
Twitter: TweetDeck to no longer allow concurrent actions from multiple accounts »

Twitter's Yoel Roth…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 28

    Feb

  • 07

    Mar

MO

Altria Group

$64.06

-0.13 (-0.20%)

13:37
02/21/18
02/21
13:37
02/21/18
13:37
Hot Stocks
Altria Group plans to reinvest one-third of tax reform benefit in 2018 »

CFO Billy Gifford says…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

SO

Southern Company

$43.25

-0.225 (-0.52%)

13:35
02/21/18
02/21
13:35
02/21/18
13:35
Hot Stocks
Breaking Hot Stocks news story on Southern Company »

Southern Company says…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

QCOM

Qualcomm

$63.99

-0.86 (-1.33%)

, AVGO

Broadcom

$249.62

0.73 (0.29%)

13:35
02/21/18
02/21
13:35
02/21/18
13:35
Recommendations
Qualcomm, Broadcom analyst commentary  »

Stifel sees Broadcom…

QCOM

Qualcomm

$63.99

-0.86 (-1.33%)

AVGO

Broadcom

$249.62

0.73 (0.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 06

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.